Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,710 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dried Clear all
Not yet recruiting Not applicable Interventional

TearCare in Young Adults

NCT07579156
View directory record Official record
Conditions
Meibomian Gland Dysfunction (Disorder)
Interventions
TearCare®
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 29 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 20, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

NCT04523129
View directory record Official record
Conditions
Dry Eye Disease
Interventions
CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 20, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

NCT00079937
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Placebo, Fluticasone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
56
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Oct 20, 2026, 8:41 PM EDT
Completed No phase listed Observational

Prospective Health Assessment of Cataract Patients' Ocular Surface

NCT01016405
View directory record Official record
Conditions
Dry Eye
Interventions
Not listed
Lead sponsor
Innovative Medical
Industry
Eligibility
55 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2011 · Synced Oct 20, 2026, 8:41 PM EDT
Completed No phase listed Observational Results available

Pediatric Ease of Use ELLIPTA Items

NCT03315572
View directory record Official record
Conditions
Asthma
Interventions
Interviewer administered version of ease of use items, Self-administered version of ease of use items, Caregiver version of ease of use items
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Southfield, Michigan • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Oct 20, 2026, 8:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of CC-292

NCT02433457
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-292, Oral Omeprazole (OMP)
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 20, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)

NCT02121301
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Low Dose 0.155µg/mL SkQ1 ophthalmic solution, High Dose 1.55µg/mL SkQ1 ophthalmic solution, Placebo (Vehicle) opthalmic solution
Drug
Lead sponsor
Mitotech, SA
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 20, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Results available

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

NCT03546907
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
SAR440340, Placebo, Any Inhaled Corticosteroids as prescribed by treating physician as standard of care, Any Long Acting Beta Agonist as prescribed by treating physician as standard of care, Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care, Any short-acting β agonist as prescribed by treating physician as standard of care
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 75 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Los Angeles, California • Riverside, California • Rolling Hills Estates, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 20, 2026, 8:41 PM EDT
Active, not recruiting Phase 1 Interventional

Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy

NCT05820711
View directory record Official record
Conditions
Head and Neck Cancer, Xerostomia
Interventions
MSC
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 90 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 20, 2026, 8:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Dry Eye Treatments on the Ocular Surface

NCT01797822
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Dry Eye Syndrome
Interventions
Dexamethasone, Artificial tear
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 20, 2026, 8:41 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants

NCT05992922
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
IC265 Ophthalmic Solution 1%, Placebo Ophthalmic Solution (Vehicle)
Drug
Lead sponsor
Iacta Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 20, 2026, 8:41 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

NCT02130531
View directory record Official record
Conditions
Geographic Atrophy, Age-Related Macular Degeneration
Interventions
Emixustat HCl Tablet, Placebo Tablet
Drug · Other
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
65 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 20, 2026, 8:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Strawberry Consumption in Overweight and Obese Individuals

NCT04094103
View directory record Official record
Conditions
Obesity, Metabolic Syndrome
Interventions
Active strawberry powder, Placebo strawberry powder, Mixed strawberry powder
Dietary Supplement
Lead sponsor
Carl Ade, M.S., Ph.D.
Other
Eligibility
35 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Manhattan, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 20, 2026, 8:41 PM EDT
Recruiting No phase listed Observational

Agreement of Two OCT Biometers: A Pilot Study

NCT07782619
View directory record Official record
Conditions
Anterior Segment of Eye, Axial Length, Biometrics Measurement
Interventions
UNITY DX, ANTERION
Device
Lead sponsor
Alcon Research
Industry
Eligibility
21 Years and older
Enrollment
50 participants
Timeline
2026 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 20, 2026, 8:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Supporting Tailored And Responsive PrEP in Rural North Carolina

NCT05984030
View directory record Official record
Conditions
HIV Pre-Exposure Prophylaxis
Interventions
PrEP Navigation Services, Telehealth PrEP Services Referral, HealthMpowerment Digital Health Intervention - Enhanced, HealthMpowerment Digital Health Intervention - Basic
Other · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 39 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 20, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Results available

Platelet-Rich Plasma Therapy for Patellar Tendinopathy

NCT03136965
View directory record Official record
Conditions
Patellar Tendinitis
Interventions
PRP, Dry Needling, Dry Needling - Sham
Biological · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 39 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 20, 2026, 8:41 PM EDT
Completed Not applicable Interventional Results available

RCT of Mesh Versus Jet Nebulizers on Clinical Outcomes During Mechanical Ventilation in the Intensive Care Unit

NCT02056119
View directory record Official record
Conditions
Respiratory Insufficiency
Interventions
Vibrating Mesh Nebulizer Arm, Jet Nebulizer Arm
Device
Lead sponsor
Rush University Medical Center
Other
Eligibility
1 Year and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 20, 2026, 8:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease

NCT03414645
View directory record Official record
Conditions
Dry Eye, Graft-versus-host-disease, Ocular Discomfort
Interventions
CAM-101 10%, Vehicle Control, CAM-101 30%
Biological
Lead sponsor
Cambium Bio Limited
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Palo Alto, California • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 20, 2026, 8:41 PM EDT
Completed Phase 3 Interventional

A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease

NCT07284381
View directory record Official record
Conditions
Dry Eye Disease
Interventions
ABBV-444, REFRESH OPTIVE UD
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Dothan, Alabama • Chandler, Arizona • Azusa, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 20, 2026, 8:41 PM EDT
Enrolling by invitation Not applicable Interventional

Dry Needling and Exercise for Mid-portion Achilles Tendinopathy

NCT07642583
View directory record Official record
Conditions
Non-Insertional Achilles Tendinopathy
Interventions
Dry needling, Sham dry needling
Other
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 64 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 20, 2026, 8:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Overnight Pant Study for Children With Nocturnal Enuresis

NCT05178641
View directory record Official record
Conditions
Nocturnal Enuresis
Interventions
Ninjamas Pyjama Pants, Participant's Overnight Current Standard of Care
Device · Other
Lead sponsor
Procter and Gamble
Industry
Eligibility
4 Years to 7 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 20, 2026, 8:41 PM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

NCT02634853
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
1% Tavilermide Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Mimetogen Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Louisville, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 16, 2019 · Synced Oct 20, 2026, 8:41 PM EDT
Terminated Phase 2 Interventional

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

NCT04816604
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
GB002 (seralutinib), Generic Dry Powder Inhaler
Drug · Device
Lead sponsor
Gossamer Bio USA, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
15
States / cities
Sacramento, California • Santa Barbara, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 8:41 PM EDT
Completed Phase 4 Interventional

A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome

NCT02139033
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Retaine™
Drug
Lead sponsor
Ocusoft, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Oct 20, 2026, 8:41 PM EDT